Bioinformatics Study Applied to the Pharmacokinetic Profile of Chitosan and its Derivatives with Biomedical Applicability

The N-acetyl group attached to monomeric glucosamine monomer units of chitin confers an extremely low solubility, which makes chitin difficult to process and therefore limiting its medical potential. In order to be used as a drug administration system in the body, it is important to know about the pharmacokinetic profiles of chitosan and its derivatives, more specifically about ADME-Tox profiles (absorption, distribution, metabolism, excretion, and toxicology). Through cheminformatics and bioinformatics tools, ADMET is identifying, a set of pharmacokinetic characteristics, such as absorption, distribution, metabolism, blood-brain barrier, nervous system barrier, and toxicological characteristics of chitosan and 5 of its derivatives. Our results have shown that one can try to integrate the drug delivery system into the body.


Introduction
Chitosan (CS) represents a polysaccharide, usually in linear form, that is obtained by deacetylation of chitin. The critical characteristics [1] of CS have been mentioned, such as good biocompatibility, hydrophilicity, high bioavailability, reduced toxicity, and ability to form films, all these features give CS and its derivatives important capabilities to use in various medical applications [2].
Recently, a very interesting review regarding CS and its derivatives was published by D Zhao et al [2]. In this work, the main properties of chitosan-based nanoparticles and its derivatives in the field of drug delivery, antimicrobial applications, and tissue regeneration are very well presented [2].
Polysaccharide-based drug delivery systems have challenged medical treatments due to their efficient and appropriate delivery capability. Among the various polymers, chitosan-based drug delivery systems have been of great interest because they can target molecules with specific membrane receptors [2]. On the other hand, chitosan-based drug delivery systems can enter cells, and, they can assure a more protected and efficient delivery of targeted drugs to various tissue [2]. Chitosan-based drug delivery systems have been studied in various well-organized epithelia such as pulmonary [3], nasal [4], or intestinal [5]. Another property of chitosan and its derivatives that agrees these nanoparticles to be used as drug carriers and coating molecules is the accessibility of their functional groups that facilitate chemical changes. The biodegradability of chitosan is also added to its use as a drug delivery vehicle.
It was mentioned that the chitosan molecule is disposed to degradation by lysozyme and chitinase. Also, the presence of acidic environment encountered in the stomach during oral administration induces chitosan degradation [6]. While lysozyme is naturally produced on different mucosal surfaces, chitinase production has been reported by intestinal flora.
It was shown that chitosan is insoluble in most organic solvents, limiting its applicability for encapsulation and release of hydrophobic drugs [7]. For this reason, few chitosan derivatives have been proposed to increase the encapsulation efficiency of hydrophobic drugs [7]. These derivatives can form self-assembled aggregates in aqueous solutions and have been studied as carriers of hydrophobic drugs. Nanoparticles obtained by structural changes of chitosan, such as hydrophobically modified glycol chitosan (HGC), is the most studied in present, due to the suitable encapsulation and delivery of hydrophobic drugs [8].
The oral delivery of drugs represents the most convenient way of drug administration for patients. Nevertheless, several factors affected oral delivery, such: the variation of pH into stomach, the action of enzymes during drug absorption, which can reduce the permeability of the drug into the systemic circulation. Nanoparticle technology is an increasingly studied technique to cover the limitations of oral drug delivery [9]. It was mentioned several advantages of using nanoparticle such: large surface area, small particle size, and an editable surface. The small particle size is known to increase the rate of drug dissolution [10]. In this context, the physical features of drugs that regulate nasal absorption include molecular weight, hydrophobicity and electrical charge. Drugs that do not cross the nasal membrane undergo mucociliary clearance [11]. This limitation can be reduced by developing a suitable mucoadhesive system represented by chitosan derivatives-based nanoparticles. Chitosan derivatives being structurally biodegradable, biocompatible, and with low toxicity, adheres to mucus, and open tight junctions of the nasal membrane [12].
Here, using bioinformatics and cheminformatics tools, our critical aim was to predict the pharmacokinetic profiles of chitosan and its derivatives. Currently, information on the pharmacokinetic profile (absorption, distribution, metabolism, elimination) and toxicity of chitosan and its derivatives are poorly represented. Through the advanced pharmacokinetic prediction tools, we were able to (i) quantify the intestinal absorption and skin permeability of chitosan and its derivatives, (ii) predict their critical blood-brain barrier and central nervous system permeabilities, (iii) elucidate a specific metabolic way for chitosan and its derivatives.
An important part of our work was to quantify the toxicity of chitosan and its derivatives, these features being represented by (i) mutagenic effect (AMES), (ii) hepatotoxicity, and (iii) skin sensitization.
The compounds in the SMILES form were loaded into DiscoveryStudio/Build module [14]. The calculation of the minimum potential energy was performed by choosing the MMFF94 force field, gradient 0.5. After minimization, the G4 electrical charges were charged. The database was formed. https://doi.org/10.37358/RC.20.6.8191

3.Results and discussions
By in silico tools, we evaluated the predictive ADME-Tox profiles of chitosan and its derivatives. The Absorption results showed that: (i) chitosan and its derivatives presented poor intestinal absorption, these results lead to the idea that chitosan and its derivatives are not suitable for oral administration; (ii) all chitosan derivatives presented suitable permeability at Caco-2 cell line (is a continuous line of heterogeneous human epithelial colorectal) but a very low permeability at skin level. These results can suggest that chitosan and its derivatives are suitable drug delivery of drugs when their skin retention is requested ( Table 2).
Regarding the application of chitosan and its derivatives in the administration of drugs when penetration of skin barrier is critical, our results are correlated with the experimental studies [19,20] that mentioned the importance of chitosan and its derivatives in the delivery system of transdermal drugs. For Distribution parameters, especially blood-brain barrier permeability and central nervous system permeability of chitosan and its derivatives, we obtained interesting results (Table 3).
Our results show that chitosan and its derivatives are not able to penetrate CNS, log CNS are included in -7.028 (chitosan) and -4.616 (chitosan azide). Instead, for BBB, chitosan and its derivatives presented a moderate permeability. Log BBB varies from -1.301 (trimethylsilyl-chitosan) to -2.619 (chitosan). These results show that trimethylsilyl-chitosan, N-(hydroxypropyl) chitosan, Nacetylchitosan, and zinc-chitosan can represent an appropriate delivery system of drugs and brain. Our results regarding good predicted BBB permeability of chitosan and its derivatives are supported by experimental studies [21,22]. It is known that the blood-brain barrier is critical during therapies for diseases of the central nervous system. Our results following the studies that mentioned that the efficacy of brain-targeted chitosan nanoparticle uptake by human BBB brain microvessel endothelial cells [21,22]. Regarding toxicological parameters, our results show that chitosan derivatives do not have AMES toxicity except chitosan azide. Some of them show cardiotoxicity risk -N-acetylchitosan, chitosan silicate, N-hydroxypropyl chitosan, and trimethylsilyl chitosan. Our results show that chitosan derivatives do not induce hepatotoxicity and skin toxicity.
An important step in our work was to predict the non-toxicity and non-allergic characteristics of chitosan and its derivatives in accordance with other studies. A very recent study [23], which mentioned that chitosan and its derivatives are strong agents in inhibiting biofilm formation and can attenuate the properties of virulence by various pathogenic bacteria, supported our calculation results on AMES toxicity of chitosan and its derivatives. Also, our results on the hepatoprotective effects of chitosan and its derivatives agreed with the experimental data [24].

4.Conclusions
Chitosan nanoparticles can effectively deliver drugs to specific locations by retaining the drug locally to allow an extended time for drug absorption. The compounds studied by us so far have been little characterized in the literature, but quite often used in practice. Through this paper, we have succeeded in characterizing the cheminformatics and bioinformatics of the studied compounds. Important results were obtained from nano-QSAR studies by identifying the most hydrophobic/ hydrophilic structures, those that can be used as an optimal transport medium and very important ADMET study. So far no such studies exist, and therefore the paper presents important data for the pharmaceutical industry.